192.81
price up icon1.71%   3.24
after-market Handel nachbörslich: 192.82 0.010 +0.01%
loading
Schlusskurs vom Vortag:
$189.57
Offen:
$188.06
24-Stunden-Volumen:
893.07K
Relative Volume:
0.73
Marktkapitalisierung:
$26.46B
Einnahmen:
$1.96B
Nettoeinkommen (Verlust:
$-253.24M
KGV:
-101.41
EPS:
-1.9012
Netto-Cashflow:
$94.06M
1W Leistung:
+2.55%
1M Leistung:
+18.22%
6M Leistung:
+24.48%
1J Leistung:
+54.57%
1-Tages-Spanne:
Value
$188.06
$195.12
1-Wochen-Bereich:
Value
$187.16
$198.99
52-Wochen-Spanne:
Value
$120.67
$198.99

Natera Inc Stock (NTRA) Company Profile

Name
Firmenname
Natera Inc
Name
Telefon
650-249-9090
Name
Adresse
13011 MCCALLEN PASS, AUSTIN, CA
Name
Mitarbeiter
4,434
Name
Twitter
@nateragenetics
Name
Nächster Verdiensttermin
2024-11-12
Name
Neueste SEC-Einreichungen
Name
NTRA's Discussions on Twitter

Vergleichen Sie NTRA mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Diagnostics & Research icon
NTRA
Natera Inc
192.81 26.02B 1.96B -253.24M 94.06M -1.9012
Diagnostics & Research icon
TMO
Thermo Fisher Scientific Inc
558.31 210.57B 43.74B 6.59B 6.11B 17.30
Diagnostics & Research icon
DHR
Danaher Corp
214.01 153.21B 24.27B 3.50B 5.02B 4.8589
Diagnostics & Research icon
IDXX
Idexx Laboratories Inc
627.66 50.75B 4.04B 985.66M 774.34M 12.01
Diagnostics & Research icon
A
Agilent Technologies Inc
143.20 41.35B 6.79B 1.22B 1.09B 4.2644
Diagnostics & Research icon
IQV
Iqvia Holdings Inc
217.83 37.15B 15.70B 1.24B 2.01B 6.9036

Natera Inc Stock (NTRA) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-10-27 Hochstufung BNP Paribas Exane Underperform → Neutral
2025-09-22 Fortgesetzt Wells Fargo Equal Weight
2025-03-13 Eingeleitet RBC Capital Mkts Outperform
2025-01-23 Eingeleitet Barclays Overweight
2024-06-03 Fortgesetzt Jefferies Buy
2024-04-08 Fortgesetzt Craig Hallum Buy
2024-02-20 Herabstufung Raymond James Strong Buy → Outperform
2023-12-29 Bestätigt BTIG Research Buy
2023-12-14 Eingeleitet Guggenheim Buy
2023-12-13 Eingeleitet Wolfe Research Outperform
2023-11-13 Hochstufung Raymond James Outperform → Strong Buy
2023-09-28 Eingeleitet Bernstein Mkt Perform
2023-07-05 Fortgesetzt JP Morgan Overweight
2023-05-05 Eingeleitet UBS Buy
2023-01-18 Hochstufung Raymond James Mkt Perform → Outperform
2022-08-25 Eingeleitet Credit Suisse Outperform
2022-04-25 Eingeleitet Stephens Overweight
2022-03-08 Eingeleitet Goldman Buy
2022-01-06 Fortgesetzt Piper Sandler Overweight
2021-10-15 Fortgesetzt Cowen Outperform
2021-06-15 Eingeleitet Raymond James Mkt Perform
2021-05-25 Eingeleitet Wells Fargo Overweight
2021-01-28 Eingeleitet Truist Buy
2020-10-08 Eingeleitet BTIG Research Buy
2020-09-28 Eingeleitet Morgan Stanley Overweight
2020-09-17 Eingeleitet SVB Leerink Outperform
2020-06-10 Fortgesetzt Piper Sandler Overweight
2020-05-07 Hochstufung JP Morgan Neutral → Overweight
2018-10-05 Eingeleitet JP Morgan Neutral
2018-07-05 Bestätigt Piper Jaffray Overweight
2017-08-07 Bestätigt Morgan Stanley Overweight
2016-11-10 Bestätigt The Benchmark Company Buy
2016-05-23 Bestätigt The Benchmark Company Buy
2016-05-11 Bestätigt The Benchmark Company Buy
2016-04-19 Eingeleitet The Benchmark Company Buy
2015-09-28 Hochstufung Wedbush Neutral → Outperform
2015-08-14 Hochstufung Morgan Stanley Equal-Weight → Overweight
2015-08-04 Eingeleitet Robert W. Baird Outperform
2015-07-27 Eingeleitet Morgan Stanley Equal-Weight
2015-07-27 Eingeleitet Piper Jaffray Overweight
2015-07-27 Eingeleitet Wedbush Neutral
Alle ansehen

Natera Inc Aktie (NTRA) Neueste Nachrichten

pulisher
09:29 AM

Natera, known for spotting cancer recurrence, wades into early detection - statnews.com

09:29 AM
pulisher
03:49 AM

Can momentum traders help lift Natera Inc.2025 Investor Takeaways & Expert Approved Momentum Ideas - newser.com

03:49 AM
pulisher
12:57 PM

Is Natera Inc. stock positioned well for digital economy2025 Top Decliners & AI Based Buy and Sell Signals - newser.com

12:57 PM
pulisher
Oct 28, 2025

Natera reports progress in blood test for precancerous polyp detection By Investing.com - Investing.com South Africa

Oct 28, 2025
pulisher
Oct 28, 2025

Natera (NTRA) Advances in Blood-Based CRC Screening with Promisi - GuruFocus

Oct 28, 2025
pulisher
Oct 28, 2025

Natera Reports Strong Advanced Adenoma Data from Prospective PROCEED-CRC Trial, Demonstrating 22.5% Sensitivity and 91.5% Specificity - BioSpace

Oct 28, 2025
pulisher
Oct 28, 2025

Key resistance and support levels for Natera Inc.2025 Earnings Surprises & Daily Stock Trend Reports - newser.com

Oct 28, 2025
pulisher
Oct 28, 2025

Natera reports progress in blood test for precancerous polyp detection - Investing.com

Oct 28, 2025
pulisher
Oct 28, 2025

Does Signatera’s Positive Phase 3 Data Shift the Long-Term Growth Story for Natera (NTRA)? - Yahoo Finance

Oct 28, 2025
pulisher
Oct 28, 2025

Price momentum metrics for Natera Inc. explainedQuarterly Profit Summary & Smart Money Movement Alerts - newser.com

Oct 28, 2025
pulisher
Oct 28, 2025

How Recent Developments Are Reshaping the Natera Investment Story - Yahoo! Finance UK

Oct 28, 2025
pulisher
Oct 28, 2025

How high can Natera Inc. stock go2025 Bull vs Bear & High Return Trade Opportunity Guides - newser.com

Oct 28, 2025
pulisher
Oct 28, 2025

Ranking Natera Inc. among high performing stocks via toolsTrade Entry Summary & Safe Entry Point Identification - newser.com

Oct 28, 2025
pulisher
Oct 27, 2025

Automated trading signals detected on Natera Inc.Earnings Beat & Reliable Price Breakout Signals - newser.com

Oct 27, 2025
pulisher
Oct 27, 2025

Regression analysis insights on Natera Inc. performanceWeekly Profit Report & Consistent Return Strategy Ideas - newser.com

Oct 27, 2025
pulisher
Oct 27, 2025

Will Natera Inc. stock outperform Nasdaq indexJuly 2025 Update & Real-Time Chart Pattern Alerts - newser.com

Oct 27, 2025
pulisher
Oct 27, 2025

What analysts say about Natera Inc stockTrade Execution Strategies & Today’s Picks, Tomorrow’s Winners - earlytimes.in

Oct 27, 2025
pulisher
Oct 27, 2025

Natera Inc.’s New Prenatal Test Study: A Potential Game-Changer in Genetic Screening - TipRanks

Oct 27, 2025
pulisher
Oct 27, 2025

Natera’s New Study: A Potential Game-Changer in Breast Cancer Treatment - TipRanks

Oct 27, 2025
pulisher
Oct 27, 2025

Using portfolio simulators with Natera Inc. includedTake Profit & Real-Time Chart Pattern Alerts - newser.com

Oct 27, 2025
pulisher
Oct 27, 2025

Why Natera Inc. stock could see breakout soonRecession Risk & AI Forecast Swing Trade Picks - newser.com

Oct 27, 2025
pulisher
Oct 27, 2025

Natera’s FIND-CRC Study: A Potential Game-Changer in Colorectal Cancer Screening - TipRanks

Oct 27, 2025
pulisher
Oct 27, 2025

Natera Inc.’s Innovative Approach to Heart Transplant Rejection Monitoring: A Study Update - TipRanks

Oct 27, 2025
pulisher
Oct 27, 2025

Natera’s PROCEED-CRC Study: A Step Forward in Early Cancer Detection - TipRanks

Oct 27, 2025
pulisher
Oct 27, 2025

How Investors May Respond To Natera (NTRA) Signatera Data Boosting FDA Case in Bladder Cancer - simplywall.st

Oct 27, 2025
pulisher
Oct 27, 2025

November 2026 Options Now Available For Natera (NTRA) - Nasdaq

Oct 27, 2025
pulisher
Oct 27, 2025

Published on: 2025-10-27 06:35:18 - newser.com

Oct 27, 2025
pulisher
Oct 27, 2025

Published on: 2025-10-27 05:35:59 - newser.com

Oct 27, 2025
pulisher
Oct 27, 2025

Halper Sadeh LLC Encourages Natera Inc. Shareholders to Contact the Firm to Discuss Their Rights - Bluefield Daily Telegraph

Oct 27, 2025

Finanzdaten der Natera Inc-Aktie (NTRA)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading

Natera Inc-Aktie (NTRA) Insiderhandel

Insiderhandel Beziehung Datum Transaktion Kosten #Aktien Wert ($) #Aktien Gesamt
Brophy Michael Burkes
CHIEF FINANCIAL OFFICER
Oct 22 '25
Sale
186.68
920
171,746
69,189
Brophy Michael Burkes
CHIEF FINANCIAL OFFICER
Oct 24 '25
Sale
196.77
755
148,561
69,189
Brophy Michael Burkes
CHIEF FINANCIAL OFFICER
Oct 23 '25
Sale
187.16
495
92,644
69,944
diagnostics_research MTD
$1,394.17
price down icon 0.74%
diagnostics_research LH
$248.14
price down icon 4.45%
diagnostics_research WAT
$343.47
price down icon 0.72%
diagnostics_research DGX
$174.78
price down icon 1.96%
diagnostics_research IQV
$217.83
price down icon 0.14%
Kapitalisierung:     |  Volumen (24h):